Gastric Cancer
Advertisement
Dr. Cytryn reviews the FDA approval of tislelizumab and shares thoughts on its clinical impact.
A recent study reviewed global disparities in gastric cancer screening, finding limited research about screening feasibility.
Tislelizumab is a monoclonal antibody with a high affinity and binding specificity against programmed cell death protein 1.
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
A recent study utilized patient data from 13 medical centers in a biomarker analysis of 1L ICIs with & without ...
Dr. Cytryn provides insights on the FDA approval of zolbetuximab and how it will impact clinical practice.
Both of the double-blind, multicenter trials evaluated the major efficacy outcomes of PFS and OS.
A recent systematic review evaluated the relationship between NLR and the prognosis of patients who receive NAC.
The phase III study found that regorafenib improved overall survival in patients with refractory advanced gastric cancer.
The SOX chemotherapy regimen for gastric cancer consists of S-1, an oral fluoropyrimidine, in combination with oxaliplatin.
Tislelizumab shows significant survival benefits in first-line treatment for gastric and esophageal cancers.
FDA approval of the first and only CLDN18.2-targeted treatment follows two successful phase III clinical trials.
Dr. Weinberg provides a recap of all of the GI oncology data of practice-changing potential presented at ESMO 2024.
Dr. Leong showcases the highly anticipated results of the TOPGEAR study in patients with resectable G/GEJ adenocarcinoma.
The addition of preop CRT to periop chemo may not have added OS benefit for patients with resectable G/GEJ adenocarcinoma.
Dr. Wainberg reviews the data on GI malignancies and notes that it is unclear who should receive radiation before surgery.
Dr. Janjigian shares an overview of the DESTINY-Gastric03 study and the history of T-Dxd for gastric and GEJ cancers.
Trastuzumab deruxtecan, pembrolizumab, and chemotherapy shows benefits in advanced or metastatic esophageal, gastric, or GEJA
These data may support the approval of pembro plus trastuzumab and chemo in patients with HER2+ metastatic G/GEJ cancer.
Researchers utilized a deep learning model to combine data and develop personalized treatment response predictions.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.